GlassScriptPhysician profile
Paul Richardson
NPI 1124018999
$4,217.99
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,351 · 2020: $111 · 2022: $303 · 2023: $277 · 2024: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $914 · Food and Beverage: $440 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $913.86 |
| Food and Beverage | $439.65 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,523.56 | 2019 | |
| Procept Biorobotics Corporation | $1,076.66 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Astellas Pharma US INC | $535.40 | 2019-2023 | Myrbetriq, Xtandi |
| Abbvie INC. | $202.74 | 2019-2024 | |
| Pfizer INC. | $192.60 | 2019-2024 | |
| Janssen Biotech, INC. | $181.10 | 2019-2024 | Erleada, Akeega |
| Accord Healthcare, INC. | $136.31 | 2022 | |
| Merck Sharp & Dohme LLC | $113.41 | 2019 | |
| Teleflex LLC | $92.40 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.85 | 2019 | |
| Axonics, INC. | $23.26 | 2024 | Axonics |
| Convatec INC. | $22.56 | 2023 | |
| Progenics Pharmaceuticals, INC. | $17.33 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $16.85 | 2019 | |
| Urovant Sciences INC | $12.91 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $11.63 | 2020 | |
| Dendreon Pharmaceuticals LLC | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.